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Purpose: We aimed to evaluate the efficacy and safety of gemcitabine/S-1 combination 
chemotherapy for the treatment of patients with advanced biliary tract cancer.  
Methods: Patients with histologically or cytologically confirmed unresectable or recurrent 
biliary tract cancer were eligible for inclusion.  The primary endpoint was overall survival.  
Gemcitabine was administered intravenously at a dose of 1,000 mg/m2 over 30 min on days 
1 and 8 and oral S-1 was administered daily at a dose of 60 mg/m2 on days 1–14.  This 
schedule was repeated every 3 weeks until disease progression or patient refusal. 
Results: Twenty-five patients were enrolled between October 2007 and January 2009. 
Eleven patients (44%) had extrahepatic bile duct cancer, 5 (20%) had intrahepatic bile duct 
cancer, 8 had gallbladder cancer (32%) and 1 (4%) had ampulla of Vater cancer.  The 
median overall survival time was 12.7 months (95% CI, 8.4–23.5 months) and the 1-year 
survival rate was 52.0% (95% CI, 31.2–69.2%).  Of the twenty-three patients with evaluable 
target regions, seven patients experienced a partial response and an overall response rate 
was 30.4%. The following grade 3-4 hematological toxicities occurred: neutropenia (56%), 
leukopenia (24%), anemia (8%) and thrombocytopenia (4%).  In spite of the high incidence of 
grade 3–4 neutropenia, no patients developed febrile neutropenia in the present study. The 
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major grade 3-4 non-hematological toxicities were fatigue (8%), anorexia (8%) and diarrhea 
(4%). 
Conclusions: Gemcitabine/S-1 combination chemotherapy offered a promising survival 
benefit with acceptable toxicity in patients with advanced biliary tract cancer. 
Keywords: Biliary tract cancer - Gemcitabine - S-1 - Chemotherapy  
 





Biliary tract cancer is one of the most lethal malignancies worldwide, with surgery 
representing the only potentially curative treatment for this disease.  However, many 
patients are diagnosed too late for curative resection, and even if surgery can be performed, 
the likelihood of relapse is very high [7, 13].  Over the past decade, gemcitabine has been 
widely used to treat unresectable or recurrent biliary tract cancer [3, 4, 9, 17, 18, 23, 27], 
although no phase III trials have established this drug as a standard treatment for advanced 
biliary tract cancer.  We have previously evaluated the outcome of consecutive 22 patients 
with advanced biliary tract cancer who received gemcitabine monotherapy as first line and 
reported that median survival time (MST) was 8.3 months (95% CI: 6.4-11.2 months) [9].   
In the ABC-02 study, the first prospective multicenter phase III study in this field, 
gemcitabine/cisplatin combination chemotherapy was compared with gemcitabine 
monotherapy. The study found that the combination regimen significantly prolonged MST 
(from 8.1 to 11.7 months; P < 0.001) [26].  The superiority of gemcitabine/cisplatin 
combination chemotherapy over gemcitabine monotherapy was also demonstrated in a 
randomized phase II study conducted in Japan (the BT-22 study) [6].  Given these findings, 
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gemcitabine/cisplatin combination chemotherapy is now becoming accepted as a new 
standard regimen for advanced biliary tract cancer.   
S-1 is an oral fluoropyrimidine prodrug that has confirmed efficacy against various solid 
tumors, both alone and in combination with other cytotoxic drugs [1, 12, 14, 19, 29].  S-1 
monotherapy has yielded good results against advanced biliary tract cancer [5, 24], and 
gemcitabine/S-1 combination therapy has yielded promising results with acceptable toxicity 
levels for patients with advanced pancreatic cancer [15,16, 28].  At the time of planning this 
clinical trial in 2007, there had been no reports on gemcitabine/S-1 combination 
chemotherapy for patients with advanced biliary tract cancer, so we designed this clinical trial 
to determine its efficacy and safety in this context. 
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Patients and methods 
Eligibility criteria 
Patients with advanced biliary tract cancer that was not amenable to potentially curative 
surgery or that had recurred after surgery were eligible for inclusion if they met the following 
criteria: histologically or cytologically confirmed biliary tract cancer; Eastern Cooperative 
Oncology Group performance status of 0–2; age ≥20 years; adequate bone marrow function 
(neutrophil count ≥1,500/mm3, and platelet count ≥100,000/mm3), liver function (total bilirubin 
≤3 times the upper limit of normal (ULN) and aspartate aminotransferase [AST]/alanine 
aminotransferase [ALT] ≤5 times ULN), and renal function (creatinine ≤1.5 mg/dL); adequate 
oral intake; life expectancy ≥3 months. All patients provided written informed consent.  
Exclusion criteria included a history of chemotherapy or radiotherapy (patients who had 
undergone adjuvant chemotherapy were not excluded if at least 6 months had passed since 
the last administration), pregnancy or lactation, a history of severe drug allergy, and other 
severe comorbid diseases.  This phase II study (UMIN ID 000000792) was conducted in five 
institutions in Japan.  The protocol was approved by the institutional review board at each 
institution and patient registration and data management were conducted at an independent 
data center at Translational Research Center, Kyoto University Hospital.  All procedures 
were performed in accordance with the 1964 Declaration of Helsinki. 




Gemcitabine was infused at a dose of 1000 mg/m2 over 30 min on days 1 and 8.  S-1 was 
given orally twice a day for 14 consecutive days. Doses of S-1 were calculated according to 
body surface area (BSA) as follows: BSA < 1.25 m2, 60 mg/day; 1.25 m2 ≤ BSA < 1.5 m2, 80 
mg/day; BSA ≥1.5 m2, 100 mg/day.  The gemcitabine and S-1 treatment regimen was 
repeated every 3 weeks.  Doses were reduced in response to adverse effects (graded 
according to the Common Terminology criteria for Adverse Events v 3.0) [22].  
Chemotherapy was started if on day 1 the neutrophil count was ≥1500/mm3, platelet count 
was ≥100,000/mm3, total bilirubin was ≤3 times the ULN, AST/ALT was ≤5 times ULN, and 
there were no non-hematological toxicities of grade 3 or higher (except for abnormal blood 
test results not relevant to the chemotherapy regimen).  Chemotherapy was continued if on 
day 8 the neutrophil count was ≥1000/mm3, platelet count was ≥75,000/mm3, total bilirubin 
was ≤3 times the ULN, AST/ALT was ≤5 times the ULN, and there were no 
non-hematological toxicities of grade 3 or higher.  If the patient did not meet the above criteria, 
chemotherapy was delayed by 1 week. If neutropenia (grade 3–4), thrombocytopenia (grade 
3–4), febrile neutropenia or non-hematological toxicity associated with gemcitabine (grade 3) 
occurred, the subsequent gemcitabine dose was reduced to 800 mg/m2.  If further toxicity 
occurred with the reduced dose, it was further reduced to 600 mg/m2.  If a further dose 
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reduction was necessary, the subsequent gemcitabine dose was reduced by 20%.  If 
diarrhea or stomatitis (grade 3–4) associated with S-1 occurred, S-1 was discontinued and 
patients were withdrawn from the study.  No dose re-escalation was allowed.  The treatment 
regimen was continued until disease progression, unacceptable toxicity including 
non-hematological toxicity of grade 4 or patient refusal occurred.  
Pretreatment and follow up evaluation 
Pretreatment evaluation included obtaining the patient’s medical history and performing a 
physical examination, imaging using contrast-enhanced computed tomography (CT) or 
magnetic resonance imaging (MRI), a complete blood cell count, serum biochemical tests, 
an electrocardiogram and chest X-rays.  During the treatment cycles, physical examinations 
and blood tests were scheduled on days 1 and 8.  Carcinoembryonic antigen (CEA) and 
carbohydrate antigen 19-9 (CA19-9) were measured at the time patients were enrolled in the 
study and every month thereafter.  Toxicity was evaluated using the Common Terminology 
criteria for Adverse Events  v3.0 [22].  
Statistical analysis 
The primary endpoint was overall survival. The secondary endpoints were toxicity and 
response rate.  Twenty-five patients were enrolled, a sample size that would allow rejection 
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of a null hypothesis of a 30% 1-year survival rate and acceptance of an alternative 
hypothesis of a 50% 1-year survival rate, with a significance level of 0.05 and a power of 80%.  
Overall survival was calculated using the Kaplan–Meier method, and was defined as the time 
from initiation of therapy to death from any cause or the final follow up.  Among patients with 
measurable target lesions, the objective response rate was evaluated according to 
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 [21].  Patients were 
enrolled between October 2007 and January 2009 and the final analysis was conducted in 
January 2010 after a 1-year follow-up period.  All analyses were conducted on an 
intention-to-treat basis and were performed using SAS version 9.2 (SAS Institute, Cary, NC, 
USA).  
 





Twenty-five patients were enrolled between October 2007 and January 2009.  The patient 
characteristics are shown in Table 1.  The median age was 63 years (range 32–78 years) 
and 18 patients (72%) were men.  Four of the 25 patients (16%) experienced recurrent 
disease after undergoing curative surgery.  Out of the 21 patients with unresectable disease, 
distant metastasis was reported in 13 patients at the time of enrollment. Eleven patients 
(44%) had extrahepatic bile duct cancer, 8 had gallbladder cancer (32%), 5 (20%) had 
intrahepatic bile duct cancer and 1 (4%) had ampulla of Vater cancer.   
Efficacy 
Seventeen patients (68%) died during the study period.  The median overall survival time 
was 12.7 months (95% CI, 8.4–23.5 months) and the 1-year overall survival rate was 52% 
(95% CI, 31.2–69.2%, p = 0.02 under a null hypothesis of 30%).  Of the 23 patients with 
target regions that were evaluable according to RECIST, 7 (30.4%) experienced a partial 
response and 13 (56.5%) had stable disease, with an overall disease control rate of 87.0%.   
Toxicity 
In total, 229 cycles of gemcitabine/S-1 combination chemotherapy were delivered, with a 
median of 7 cycles per patient (range 1–20 cycles; Table 1).  The mean relative dose 
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intensities of gemcitabine and S-1 were 75% and 84%, respectively.  The incidence rates of 
hematological and non-hematological adverse events are summarized in Tables 2 and 3, 
respectively.  The most common grade 3–4 hematological toxicity was neutropenia (56%); 
however, no instances of febrile neutropenia were observed in this study.  The incidence 
rates of grade 3–4 anemia and thrombocytopenia were 8% and 4%, respectively.  Grade 3–4 
hyperbilirubinemia and ALT was observed in 16% and 8% of patients, respectively, mostly 
associated with obstructive jaundice caused by the primary disease. Other grade 3–4 
non-hematological adverse events were fatigue (8%), anorexia (8%) and diarrhea (4%).     




In our population of patients with advanced biliary tract cancer, gemcitabine/S-1 combination 
chemotherapy achieved an MST of 12.7 months and a 1-year survival rate of 52%.  The MST 
for patients with gall bladder cancer (n = 8) was shorter (7.6 months) than that for patients 
with other cancer types (16.0 months), which is consistent with the findings of previous 
studies, and possibly reflects the more aggressive nature of gall bladder cancer [8, 10, 20].  
The proportion of patients with gall bladder cancer in our study (32%) was comparable with 
the proportions in previous randomized trials (26–39%) [6, 25, 26], so the good MST 
observed in the current study was unlikely to be simply due to tumor type selection bias.  
Furthermore, this was a multi-institution trial, and the eligibility criteria were almost identical 
to indications used for administering chemotherapy in daily clinical practice; both these 
factors are likely to have contributed to reducing selection bias.  Although comparing 
single-arm phase II studies can be problematic, our current results are comparable to those 
of Sasaki et al., who observed an MST of 11.6 months and a 1-year survival rate of 44% 
among patients with advanced biliary tract cancer treated with gemcitabine/S-1 combination 
chemotherapy [20](Table 4).  Their treatment schedule differed slightly from ours: it 
consisted of 1000 mg/m2 gemcitabine on days 1 and 15, and 80 mg/m2 S-1 daily for 14 
consecutive days every 4 weeks.  In this study, grade 3–4 neutropenia was observed in 56% 
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of patients and this often caused suspension of chemotherapy on day 8.  In fact, planned 
chemotherapy administration on day 8 needed to be suspended in 28.5% of cycles.  
Meanwhile, Sasaki et al. reported grade 3–4 neutropenia was 34% and their regimen might 
have an advantage of avoiding suspension of chemotherapy due to neutropenia because 
gemcitabine administration was scheduled on day 1 and 15, not on day 8 with 2 week interval.  
Interestingly, a previous study of gemcitabine/cisplatin combination therapy in Japanese 
patients (BT-22 study) yielded a 56.1% incidence rate of grade 3–4 neutropenia, whereas in 
ABC-02 study involving the same regimen, the rate was only 22.6% among Caucasian 
patients [6, 26]. Although we need to take into account the difference of treatment duration 
between 2 studies (up to 24 weeks in ABC-02 study versus up to 48 weeks in BT-22 study), it 
is tempting to speculate that ethnic differences exist between patients with biliary tract cancer 
in terms of susceptibility to gemcitabine-related neutropenia. In spite of the high incidence of 
grade 3–4 neutropenia in the present study, no patients developed febrile neutropenia, 
probably due to the short duration of neutropenia caused by this combination therapy.  Aside 
from AST/ALT elevation, the most common non-hematological toxicity was fatigue (52%); 
however, the incidence rates of grade 3–4 toxicities were relatively low, showing that this 
regimen was generally well tolerated in an outpatient setting.  The grade 3–4 
hyperbilirubinemia observed in this study was associated with obstructive jaundice caused 
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by the primary disease, and so was unlikely to be relevant to the combination therapy 
regimen.  In vitro study also demonstrated the advantage of gemcitabine/S-1 combination.  
Yoshizawa et al. tested the combination of S-1 with other anti-cancer drugs (gemcitabine, 
cisplatin, irinotecan, mitomycin C, adriamycin, and paclitaxel) and reported that synergic 
effect was most evident in gemcitabine/S-1 combination [30].  The combination of 
gemcitabine and another oral fluoropyrimidine, capecitabine, was found to be similarly 
efficacious in previous single-arm phase II studies [2, 10, 11].  In their respective studies, 
Cho et al. observed an MST of 14 months and a 1-year survival rate of 58% [2], and Knox et 
al. also observed an MST of 14 months and a 1-year survival rate of 49% [10].  Koeberle et al. 
found similar results, with an MST of 13.2 months [11](Table 4).  Koeberle et al. also 
highlighted the importance of maintaining a balance between treatment efficacy and quality 
of life in palliative chemotherapy for advanced biliary tract cancer.  From the point of view of 
quality of life, combination therapy using oral fluoropyrimidines has the major advantage of 
being very convenient to administer.  Clearly, we must be cautious about the interpretation of 
data from single-arm phase II studies; however, the combination of gemcitabine and oral 
fluoropyrimidines can be used for patients with advanced biliary tract cancer in situations that 
preclude the use of cisplatin (e.g. allergy to cisplatin or intolerance to fluid infusion 
before/after cisplatin administration).  In summary, gemcitabine/S-1 combination 
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chemotherapy yielded a promising survival benefit with acceptable toxicity in patients with 
advanced biliary tract cancer. We believe that this regimen would be a good candidate for the 
experimental arm of a future phase III trial of gemcitabine/cisplatin combination therapy.  
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Table 1. Characteristics of patients with advanced biliary tract cancer (n = 25) 
 
Sex  
    Male 18 (72.0%) 
    Female 7 (28.0%) 
Median age (years) 63 (range 32–78) 
Primary lesion  
    Intrahepatic 5 (20.0%) 
    Extrahepatic 11 (44.0%) 
    Gallbladder 8 (32.0%) 
    Ampulla of Vater 1 (4.0%) 
Disease status  
    Unresectable 21 (84.0%) 
    Recurrent* 4 (16.0%) 
Target lesion  
    Primary 18 
    Liver 7 
    Lymph node 3 
    Peritoneum 2 
    Local recurrence 2 
Lung 1 
None 2 
Median no. treatment cycles 7 (range 1–20) 
Median CEA (ng/mL)     4.5 (range 0.3–468) 
Median CA19-9 (U/mL)     167 (range 1–6373) 
CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen. 
* One patient had a history of adjuvant chemotherapy using gemcitabine. 
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Table 2. Hematologic adverse events among patients with advanced biliary tract cancer 
treated with gemcitabine/S-1 combination chemotherapy (n = 25)     
 




Neutropenia  0 5 12 2 56 
Leukopenia 1 9 6 0 24 
Anemia 5 7 1 1 8 
Thrombocytopenia 1 4 1 0 4 
Febrile neutropenia – – 0 0 0 
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Table 3. Non-hematological adverse events among patients with advanced biliary tract cancer 
treated with gemcitabine/S-1 combination chemotherapy (n = 25) 
 









Fatigue 8 3 2 0 8 52 
Anorexia 3 2 2 0 8 28 
Diarrhea 1 4 1 0 4 24 
Constipation 1 6 0 0 0 28 
Rash 9 3 0 0 0 48 
Fever 8 3 0 0 0 44 
Hand-foot rash 7 3 0 –  0 40 
Infection-other 8 2 0 0 0 40 
Nausea 3 2 0 0 0 20 
Stomatitis 5 1 0 0 0 24 
Allergic reaction 4 1 0 0 0 20 
Hyperpigmentation 8 0 –  –  0 32 
Alopecia 3 0 –  –  0 12 
Injection site 
reaction 2 0 0 – 0 8 
Vomiting 1 0 0 0 0 4 
Hyperbilirubinemia 3 1 4 0 16 32 
AST 11 5 0 0 0 64 
ALT 8 4 2 0 8 56 
Creatinine 3 0 0 0 0 12 
AST, aspartate aminotransferase; ALT, alanine aminotransferase. 
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Table 4. Results of clinical trials of gemcitabine and oral fluoropyrimidine combination 
chemotherapy for the treatment of advanced biliary tract cancer 
 
  Present 
study 
Sasaki et al. 
[19] 
Knox et al. 
[10] Cho et al. [2] 
Koeberle et al. 
[11] 
Oral fluoropyrimidine S-1 S-1 Capecitabine Capecitabine Capecitabine 
MST (months) 12.7 11.6 14 14 13.2 
1-year survival rate (%) 52 44 49 58 N/A 
Prevalence of gall 
bladder cancer (%) 32 40 49 16 18 
Incidence of grade 3–4 
neutropenia (%) 56 34 34 11 11
a
 
Incidence of grade 3–4 
anorexia (%) 8 3 N/A 2 7 
Incidence of grade 3–4 
fatigue (%) 8 N/A 4 0 11 
Sample size 25 35 45 44 44 
MST, median survival time; N/A, not available. aThese subjects had leukopenia. 
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